Cell Therapy Market Is Expected To Reach a Revenue Of USD 32.5 Bn By 2033, At 18.6% CAGR | Dimension Market Research
June 10, 2024 12:01 ET
|
Dimension Market Research
New York, June 10, 2024 (GLOBE NEWSWIRE) -- Market Overview The Global Cell Therapy Market size is expected to reach USD 7.0 billion by 2024 and is further anticipated to reach USD 32.5 billion by...
CDMO Market Forecast USD 530.3 Billion by 2033 at 7.7% CAGR Growth Rate | Dimension Market Research
June 10, 2024 10:57 ET
|
Dimension Market Research
New York, June 10, 2024 (GLOBE NEWSWIRE) -- Overview The Global CDMO Market size is expected to reach USD 272.4 billion by 2024 and is further anticipated to reach USD 530.3 billion by 2033 at a...
Biopharmaceutical Market to Reach USD 1,829.2 Billion by 2033, Growing at 15.4% CAGR | Dimension Market Research
June 10, 2024 10:12 ET
|
Dimension Market Research
New York, June 10, 2024 (GLOBE NEWSWIRE) -- Overview: The Global Biopharmaceutical Market size reached USD 436.7 billion in 2023 and is further anticipated to reach USD 1,829.2 billion by 2033...
Rhino Health to Deliver Enterprise Federated Computing Solutions in Collaboration With NVIDIA
June 10, 2024 05:00 ET
|
Rhino Health
BOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- Rhino Health, the global leader in federated computing, today announced a collaboration with NVIDIA to provide an enterprise-hardened federated computing...
Rhino Health to Deliver Federated Computing Platform to Regulated Industries with Google Cloud
June 03, 2024 05:00 ET
|
Rhino Health
Rhino Health and Google Cloud announce partnership for Federated Learning to connect data silos in life sciences, healthcare, financial services, and more
Lipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 in Oral Lichen Planus
May 31, 2024 08:00 ET
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 in Oral Lichen Planus
Cellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024
May 29, 2024 16:30 ET
|
Cellectis Inc.
NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Optimi Health Secures Import Permit from Mind Medicine Australia for MDMA and Psilocybin Capsules
May 29, 2024 08:00 ET
|
Optimi Health Corp.
Optimi Health preparing to export 160 doses of MDMA and psilocybin under Australia’s Authorized Prescriber Scheme.
Vyluma Announces Marketing Authorization Application Validation for the European Union
May 29, 2024 07:30 ET
|
Vyluma, Inc.
Vyluma announces Marketing Authorisation Application (MAA) validation for the EU for NVK002 to slow the progression of pediatric myopia.
Cellectis Reports Financial Results for First Quarter 2024
May 28, 2024 16:30 ET
|
Cellectis Inc.
• Cellectis announced completion of the additional equity investment of $140M by AstraZeneca • Cash position of $143 million as of March 31, 20241; cash runway projection into 20262 • Conference...